Outlook Therapeutics jumps on plans to resubmit marketing application for eye disease treatment

Outlook Therapeutics

26/05/2026 13:27

** Shares of drug developer Outlook Therapeutics OTLK.O rise 58% to 49 cents premarket
** Co says it plans to resubmit a marketing application for its eye disease treatment in June after the U.S. FDA declined to approve it in December 
** OTLK's treatment, Lytenava, targets wet age-related macular degeneration, a common eye disease that causes vision loss due to leaking blood vessels in the retina
** In its formal response to an appeal from Outlook, the FDA concluded that substantial evidence of effectiveness for Lytenava has been established, OTLK says 
** Lytenava is a specific, officially authorized formulation of FDA-approved drug bevacizumab
** Up to last close, stock down 80% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))